Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + oxaliplatin + tegafur + gimeracil + oteracil + olaparib
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Intraperitoneal
01
Overview
PISOXO is an experimental neoadjuvant combination therapy regimen developed by Ruijin Hospital for the treatment of locally-invaded gastric cancer (LIGC). The regimen integrates three distinct therapeutic modalities: Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) using docetaxel to target peritoneal disease, systemic SOX chemotherapy (comprising intravenous oxaliplatin and the oral fluoropyrimidine S-1, which contains tegafur, gimeracil, and oteracil), and the PARP inhibitor olaparib. This multi-modal approach is designed to provide both localized control of peritoneal micrometastases and systemic control of the primary tumor and distant disease. Olaparib is included to potentially exploit DNA repair deficiencies in gastric cancer cells, thereby enhancing the cytotoxic effects of the platinum-based chemotherapy (oxaliplatin) through synthetic lethality or potentiation of DNA damage.
- Other names
- PIPAC+SOX+OLAPARIBPIPAC-SOX-Olaparibb-Ruijin Hospital-gastric cancer
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))DNAOPRT (Orotidine 5'-phosphate decarboxylase)DPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on docetaxel + oxaliplatin + tegafur + gimeracil + oteracil + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + oxaliplatin + tegafur + gimeracil + oteracil + olaparib.